Posttraumatic Stress Disorder
Conditions
Keywords
posttraumatic stress disorder, losartan, angiotensin receptor blocker
Brief summary
This study is being conducted to determine if losartan, an angiotensin receptor blocker (ARB), is safe and effective in the treatment of posttraumatic stress disorder (PTSD) symptoms. The study is also intended to determine if certain genetic markers are useful in predicting PTSD symptom reduction with losartan. Approximately 160 subjects with chronic PTSD ages 18-65 will participate in this study across five sites. Subjects will be assigned by chance to take either flexibly dosed losartan (up to a maximum dosage of 100 mg) or placebo (which resembles the study drug but has no active ingredients), once a day for 10 weeks. Furthermore, it is hypothesized that CC homozygotes for rs4311 SNP in the ACE gene will have a superior response to losartan on PTSD symptoms compared to T carriers.
Detailed description
There are limited current treatments available for PTSD, and the only FDA-approved medications are SSRIs, which were empirically found to be somewhat helpful. Losartan provides a potentially important and exciting development in that it is readily available, safe, inexpensive (available as a generic drug), and has a neurobiological mechanism based on recent exciting discoveries, as outlined below. This proposal is designed to test, in a multisite RCT, this novel, mechanistically-determined, safe and well-tolerated, potentially powerful treatment for PTSD symptoms.
Interventions
DRUGlosartan
Angiotensin receptor blocker (ARB)
DRUGPlacebo
Placebo
Sponsors
Mclean Hospital
Massachusetts General Hospital
Henry M. Jackson Foundation, Walter Reed National Military Medical Center
Foundation for Atlanta Veterans Education and Research, Inc.
NYU Langone Health
George Washington University
University of California, San Diego
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
\[Below is a synopsis of relevant eligibility criteria. For details please refer to the protocol by contacting the Principal Investigator\] Inclusion Criteria 1. Subject must be a man or woman between 18 and 70 years of age, inclusive. 2. Subjects must have a primary DSM-5 diagnosis of Posttraumatic Stress Disorder. 3. Subjects must have a Clinical Administered PTSD Scale for PTSD (CAPS-5) ≥ 25 persistent at Screening for at least 3 months duration. 4. Subject must be willing and able to adhere to the prohibitions and restrictions specified in this protocol. 5. Subject must be willing and able to fill out self-administered questionnaires. 6. Subject must be able to be compliant with self-administration of medication. 7. Subject must be able to swallow the study medication whole with aid of water. 8. Subject must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
Exclusion criteria
1. Subjects who have current or imminent risk of suicide as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS) at each study visit. 2. Subject with active psychosis. 3. Subject has a history of moderate or severe drug or alcohol use disorder according to DSM-5 criteria within 3 months before screening. 4. Subject has a history of allergy to losartan or other angiotensin receptor blockers (ARBs). 5. Subject has a medical illness likely to result in imminent hospitalization or for which treatments are contraindicated based on lab results, medical history and physical exam. 6. Subject has serious cognitive impairment felt likely to interfere with the ability to participate meaningfully in the study. Participants with mild to moderate traumatic brain injury (TBI) will not be excluded from the study. Only those who evidence significant cognitive impairment at Screening (as evidenced by confusion, inability to track discussion or answer questions, or other clear and significant indicators of cognitive impairment) will be excluded. 7. Concurrent ACE Inhibitors or Angiotensin Receptor Blockers or Prazosin; patients on other antihypertensives may be enrolled if, after consultation with their prescribing physician, it is determined that the addition of losartan would not be contraindicated. 8. Concurrent antidepressants or antipsychotics. Subjects, who have elected, in consultation with their health care provider, to discontinue any antidepressants or antipsychotics, must be off the medications for a minimum of 2 weeks prior to study randomization. Stable bedtime doses of sleep agents (e.g., trazodone ≤ 200mg; eszopiclone; zolpidem; lorazepam) will be allowed as long as the dose has been stable for at least 2 weeks prior to study randomization. Benzodiazepines taken for other than sleep are not permitted. 9. Subject is a woman who is pregnant, or breast-feeding, or planning to become pregnant. 10. Subject is unable to comply with the study-specific requirements 11. Subjects with abnormal liver, renal or EKG findings as determined by physician. 12. Subject exhibits clinically-significant hypertension as determined by medical evaluation and/or BP \> 190/100. 13. Systolic Blood Pressure (SBP) \< 90mmHg. 14. Liver function Tests (LFT's) \> 2 times the upper limit of normal. 15. Patients with Chronic Kidney Disease 4, as determined by history, baseline labs (including eGFR \< 45ml/minute) and evaluation by a physician will be excluded
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm. | 10 weeks | Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week. The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan. | 10 weeks | The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Losartan Losartan flexibly dosed from 25-100 mg per day over 10 weeks
losartan: Angiotensin receptor blocker (ARB) | 75 |
| Placebo Placebo flexibly dosed from 25-100 mg per day over 10 weeks
Placebo: Placebo | 74 |
| Total | 149 |
Baseline characteristics
| Characteristic | Losartan | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 36.4 years STANDARD_DEVIATION 12.3 | 35.5 years STANDARD_DEVIATION 12.6 | 36.0 years STANDARD_DEVIATION 12.4 |
| CAPS-5 Total | 33.5 units on a scale STANDARD_DEVIATION 10.3 | 34.2 units on a scale STANDARD_DEVIATION 10 | 33.8 units on a scale STANDARD_DEVIATION 10.2 |
| Race (NIH/OMB) American Indian or Alaska Native | 3 Participants | 1 Participants | 4 Participants |
| Race (NIH/OMB) Asian | 7 Participants | 2 Participants | 9 Participants |
| Race (NIH/OMB) Black or African American | 8 Participants | 14 Participants | 22 Participants |
| Race (NIH/OMB) More than one race | 6 Participants | 11 Participants | 17 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 1 Participants | 2 Participants | 3 Participants |
| Race (NIH/OMB) White | 50 Participants | 44 Participants | 94 Participants |
| Sex: Female, Male Female | 43 Participants | 54 Participants | 97 Participants |
| Sex: Female, Male Male | 32 Participants | 20 Participants | 52 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 75 | 0 / 74 |
| other Total, other adverse events | 20 / 75 | 18 / 74 |
| serious Total, serious adverse events | 2 / 75 | 1 / 74 |
Outcome results
Primary
The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm.
Clinician-Administered PTSD Scale for DSM-5 also known as CAPS-5 is the gold standard in PTSD assessment. The CAPS-5 is a 30-item structured interview that can be used to, make current (past month) diagnosis of PTSD, make a lifetime diagnosis of PTSD and assess PTSD symptoms over the past week. The CAPS-5 as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.
Time frame: 10 weeks
Population: Modified Intent to Treat (mITT) Population
| Arm | Measure | Value (MEAN) |
|---|---|---|
| Losartan | The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm. | -15.96 score on a scale |
| Placebo | The Primary Outcome for This Study is Mean Change in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Over the Treatment Period of 10 Weeks Between the Losartan Arm and the Placebo Arm. | -16.89 score on a scale |
p-value: 0.66Mixed Models Analysis
Secondary
Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan.
The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) as used here has 20 items, each scored 0-4, to yield a score with a possible range of 0-80. Higher scores mean worse outcome.
Time frame: 10 weeks
Population: Subjects on Losartan Arm
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Losartan | Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan. | 16.7 score on a scale | Standard Deviation 10.1 |
| Placebo | Change in CAPS-5 Associated With CC Homozygosity for rs4311 SNP in the Angiotensin Converting Enzyme Gene (ACE) Compared to T Carriers, Among Subjects Randomized to Losartan. | 15.8 score on a scale | Standard Deviation 13.1 |
p-value: 0.57Mixed Models Analysis